For and against: General priority for atypical neuroleptics;Pro und kontra: Grundsätzlicher vorrang für atypika

Psychiatrische Praxis

Volumn 32, Issue 4, 2005, Pages 163-166

  Naber, Dieter ^a   Dose, Matthias ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Bezirkskrankenhaus Taufkirchen ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; COGNITION; DIABETES MELLITUS; DRUG INDUSTRY; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; REVIEW; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUG COSTS; GERMANY; HUMANS; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 18944404873     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834708     Document Type: Review

References (20)

1. Zimbroff D, Kane J, Tamminga J, Daniel D, Mack R, Wozniak P, Sebree T, Wallin B, Kashkin K, The S. Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782-791
2. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564
3. Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Databese Syst Rev, 2002; 2: CD001357
4. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999; 25: 233-255
5. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents? Am J Psychiatry 2002; 159: 103-108
6. Csernansky JG, Ramy M, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
7. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
8. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3-10
9. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Res 2000; 43: 135-145
10. Hamann J, Leucht S, Kissling W. Are the second generation antipsychotics cost-effective? A critical review on the backgeround on different health systems. Pharmacopsychiatry 2003; 36: 18-26
11. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667
12. Davis JM, Chen N, Glick ID. A Meta-analysis of the Efficacy of Second-Generation Antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564
13. Geddes J, Harrison P, Freemantle N. New generation versus conventional antipsychotics. Lancet 2003; 362: 404
14. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589
15. Als-Nielsen B, Chen W, Gluud C, Kjaergaard LL. Association of funding and conclusions in randomised drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928
16. Rosenheck R, Perlick D, Bingham S et al. Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia. JAMA 2003; 290: 2693-2702
17. Weinmüller B. Die neuroleptische Therapie schizophrener Psychosen: eine naturalistische, retrospektive Untersuchung zur Behandlungswirklichkeit in einem Krankenhaus mit Vollversorgungsauftrag. Dissertation. München: Fakultät für Medizin der Technischen Universität München, 2005
18. Gilmer TP, Dolder CR, Lacro JP et al. Adherence to Treatment with Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia. Am J Psychiatry 2004; 161: 692-699
19. Keefe RS, Seidman LJ, Christensen BK. Comparative Effects of Atypical and Conventional Antipsychotic Drugs on neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol. Am J Psychiatry 2004; 161: 985-995
20. Paton C, Lelliott P, Harrington M et al. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003; 17: 223-239